• F Kerbaul, F Collart, M Bonnet, J Villacorta, C Guidon, and F Gouin.
• Département d'anesthésie-réanimation adulte, CHU La Timone, 126, rue Saint-Pierre, 13385 Marseille 5, France. fkerbaul@yahoo.fr
• Ann Fr Anesth Reanim. 2003 Jul 1; 22 (7): 609-28.

ObjectiveTo review the perioperative anaesthetic management of ventricular assist devices.Data SourcesExtraction from Pubmed database of french and english articles on the perioperative anaesthetic management of ventricular assist devices for 15 years.Data SelectionThe collected articles were reviewed and selected according to their quality and originality. The more recent data were selected.Data SynthesisCardiac transplantation is an effective treatment for patients in end stage cardiac failure, but the average waiting time of 17 months, associated with the lack of organs (357 out of 832 candidates were transplanted in 1996) results in a high number of deaths in patients awaiting transplantation. The appearance in the 1980's, of the first ventricular assist device (VAD) provided a new possibility for the management of patients with end-stage cardiac failure awaiting transplantation ("bridge to transplant"). The perioperative anaesthetic management of these patients is complex. End stage cardiac failure, poorly responsive to pharmacological interventions, results rapidly in secondary organ dysfunctions. VADs produce a rapid improvement in haemodynamic, renal, hepatic and neuro-endocrine functions over a 2 months period, allowing transplantation to take place under optimal conditions. However VADs are not without complications (1 year mortality of 20%), of which the major are: infections (40%), perioperative haemorrhage (30%) and thrombo-embolic sequelae (30%). A best knowledge of pathophysiology of these complications is necessary to an optimal management of patients with ventricular assist devices.

13 keywords...

hide…